Glaucoma Market: Epidemiology, Therapies, Companies, DelveInsight | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharma

Glaucoma therapies, such as ROCKLATAN/ ROCLANDA (netarsudil/latanoprost, 0.02%/0.005%), DURYSTA (bimatoprost SR), NCX-470, TRS01, and others, are expected to boost the Glaucoma Market in the upcoming years.

DelveInsight has launched a new report on "Glaucoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Glaucoma market report @ https://www.delveinsight.com/report-store/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Glaucoma Market Report:

In 2022, the total number of diagnosed prevalent cases of glaucoma in the 7MM was estimated to be approximately 7,045,443, while the overall prevalence burden of glaucoma was about 16,632,421 cases across the 7MM. The US had the highest number of diagnosed glaucoma patients, followed by Japan, Germany, and France. Open-angle glaucoma was the most prevalent type of glaucoma, contributing significantly to the overall burden in the 7MM.
According to DelveInsight's estimates, the US dominated the glaucoma market in 2022, with net sales revenue of USD 2,571 million, while the UK had the smallest market, with a size of approximately USD 132 million. The current glaucoma treatment market includes therapies such as prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, fixed combinations, alpha-2-selective adrenergic agonists, and others.
The overall glaucoma market is expected to grow during the forecast period, driven by the introduction of emerging therapies like iDose TR (travoprost intraocular implant), NCX 470, PDP-71, and others.
A significant proportion of glaucoma cases go undiagnosed due to various factors. According to DelveInsight estimates, out of approximately 16.6 million prevalent glaucoma cases in the 7MM in 2022, only about 7 million were formally diagnosed. The United States reported the highest number of diagnosed glaucoma cases among these countries, with around 2.45 million in 2022-accounting for nearly 35% of all diagnosed cases in the region-followed by Japan, which represented about 23% of the diagnosed population.
In December 2023, Glaukos Corporation received FDA approval for iDose TR, a micro-invasive, long-duration implant designed to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This titanium-based implant delivers a continuous, preservative-free dose of travoprost directly into the eye, aiming to improve adherence by reducing the need for daily eye drops. The approval was based on two Phase 3 trials involving over 1,100 participants.
Key Glaucoma companies such as Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others are evaluating new drugs for Glaucoma to improve the treatment landscape.
Promising Glaucoma therapies include ROCKLATAN/ ROCLANDA (netarsudil/latanoprost, 0.02%/0.005%), DURYSTA (bimatoprost SR), NCX-470, TRS01, and others.

Glaucoma Overview

Glaucoma is a group of eye conditions that cause characteristic cupping of the optic disc and visual field defects due to the loss of retinal ganglion cells. It is a progressive disease and the leading cause of irreversible blindness globally. The two main types are open-angle glaucoma (OAG) and narrow-angle (angle-closure) glaucoma (ACG). Often called the "silent thief of sight," glaucoma usually shows no symptoms in the early stages, and it gradually narrows peripheral vision as it progresses.

Although glaucoma is not curable, early detection and proper treatment can help prevent further damage to the optic nerve (ON). Diagnosing glaucoma typically involves a comprehensive eye exam with tests such as tonometry (measuring intraocular pressure), ophthalmoscopy (examining the optic nerve for damage), visual field testing (perimetry), and gonioscopy (assessing the eye's drainage angle). Guidelines for diagnosing glaucoma may vary by region or medical society, including recommendations from the American Academy of Ophthalmology and the European Glaucoma Society.

Glaucoma Market Outlook

The main goal of glaucoma management is to lower intraocular pressure (IOP), typically achieved through medications like prostaglandin analogs, beta-blockers, alpha-agonists, ROCK inhibitors, and carbonic anhydrase inhibitors. However, some patients may continue to experience optic nerve damage even with controlled IOP. Beyond medications, treatment options often include laser procedures and surgical interventions.

The introduction of emerging therapies such as NCX 470 (by Nicox Ophthalmics), PDP-716 (by SPARC/Visiox Pharma), and others is expected to drive positive growth in the market. In 2022, the glaucoma market size in the 7MM was approximately USD 4.07 billion, with projections indicating substantial growth by 2034.

Discover how the Glaucoma market is rising in the coming years @ https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Glaucoma Marketed Drugs
ROCKLATAN/ ROCLANDA (netarsudil/latanoprost, 0.02%/0.005%): Aerie Pharmaceuticals
DURYSTA (bimatoprost SR): AbbVie Inc.
Glaucoma Emerging Drugs
NCX-470: Nicox Ophthalmics
TRS01: Tarsier Pharma

Scope of the Glaucoma Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Glaucoma Companies: Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others
Key Glaucoma Therapies:ROCKLATAN/ ROCLANDA (netarsudil/latanoprost, 0.02%/0.005%), DURYSTA (bimatoprost SR), NCX-470, TRS01, and others
Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies
Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Glaucoma Unmet Needs, KOL's views, Analyst's views, Glaucoma Market Access and Reimbursement

To know what's more in our Glaucoma report, visit https://www.delveinsight.com/report-store/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Glaucoma Market Report:
Glaucoma market report covers a descriptive overview and comprehensive insight of the Glaucoma Epidemiology and Glaucoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Glaucoma market report provides insights into the current and emerging therapies.
The Glaucoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Glaucoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Glaucoma market.

Got queries? Click here to know more about the Glaucoma market Landscape https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Glaucoma Patient Share (%) Overview at a Glance
5. Glaucoma Market Overview at a Glance
6. Glaucoma Disease Background and Overview
7. Glaucoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Glaucoma
9. Glaucoma Current Treatment and Medical Practices
10. Unmet Needs
11. Glaucoma Emerging Therapies
12. Glaucoma Market Outlook
13. Country-Wise Glaucoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Glaucoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Glaucoma Market Outlook 2034 https://www.delveinsight.com/report-store/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Glaucoma Pipeline Insights, DelveInsight

"Glaucoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Glaucoma market. A detailed picture of the Glaucoma pipeline landscape is provided, which includes the disease overview and Glaucoma treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.